Home › Arkansas › Bills
Bills

Arkansas Congressional Bills

Browse federal bills sponsored by your state's delegation.

Bill results

in committee · Arkansas · House May 18, 2021

HR 1592: Stop Forced Organ Harvesting Act of 2021

Stop Forced Organ Harvesting Act of 2021 This bill establishes specified measures to combat forced organ harvesting and the international trafficking in persons for the purpose of removing their organs. These measures include (1) establishing property-blocking and visa-blocking sanctions, (2) prohibiting exports of certain surgery devices to entities that are identified as being responsible for forced organ harvesting or related human trafficking, and (3) requiring the Department of State to report on these practices.
Christopher H. Smith (R) · 36 co-sponsors
in committee · Arkansas · House May 18, 2021

HR 1518: 21st Century NICS Act

21st Century NICS Act This bill modifies procedures for conducting firearms-related background checks through the national instant criminal background check system (NICS). Specifically, it permits the NICS to query an additional database—the National Data Exchange—as part of a firearm-related background check.
Tom Rice (R) · 49 co-sponsors
in committee · Arkansas · House May 17, 2021

HR 3268: Combatting COVID Unemployment Fraud Act of 2021

Combatting COVID Unemployment Fraud Act of 2021 This bill requires additional documentation for individuals seeking pandemic unemployment assistance, requires state unemployment agencies to use designated fraud prevention tools, and otherwise addresses pandemic-related unemployment benefits.
Kevin Brady (R) · 42 co-sponsors
in committee · Arkansas · House May 14, 2021

HR 3203: To enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes.

This bill waives certain eligibility requirements for hospitals participating in the 340B drug discount program (i.e., a program that allows entities to receive covered outpatient drugs at reduced prices from manufacturers) during the COVID-19 (i.e., coronavirus disease 2019) public health emergency. Specifically, the bill waives the required minimum proportion of low-income patients served for hospitals that began participating in the program during or prior to the COVID-19 emergency.
Doris O. Matsui (D) · 41 co-sponsors
in committee · Arkansas · House May 14, 2021

HR 3191: COVID–19 Origin Act of 2021

COVID-19 Origin Act of 2021 This bill requires the Office of the Director of National Intelligence (ODNI) to declassify all information relating to potential links between the Wuhan Institute of Virology and the origin of COVID-19. The ODNI shall submit to Congress an unclassified report containing such information, with redactions only as necessary to protect sources and methods.
Mike Gallagher (R) · 24 co-sponsors
in committee · Arkansas · Senate May 13, 2021

SRES 213: A resolution recognizing the importance of the United States-Republic of Korea relationship to safeguarding peace, security and prosperity on the Korean Peninsula, in the Indo-Pacific region and beyond, and welcoming the visit of President Moon Jae-in to the United States.

This resolution welcomes President Moon Jae-in of South Korea to the United States. It also reaffirms the importance of the U.S.-South Korea relationship to peace, security, and prosperity on the Korean Peninsula and in the Indo-Pacific region.
Robert Menendez (D) · 11 co-sponsors
in committee · Arkansas · Senate May 13, 2021

SRES 212: A resolution establishing a McCain-Mansfield Fellowship Program in the Senate.

This resolution requires the Office of the Sergeant at Arms and Doorkeeper of the Senate to establish a McCain-Mansfield Fellowship Program through which certain veterans may participate in a two-year fellowship in the personal office of a Senator.
Mike Rounds (R) · 10 co-sponsors
in committee · Arkansas · Senate May 13, 2021

S 1604: Operation Warp Speed Act of 2021

Operation Warp Speed Act of 2021 This bill modifies procedures for Emergency Use Authorization (EUA) and provides additional authority to the Department of Health and Human Services (HHS) for vaccine production in response to a public health emergency. It also makes changes to the administration of the Strategic National Stockpile. (An EUA temporarily authorizes use of an otherwise unapproved medical product or device in certain emergency situations.) Among other modifications, the bill places additional requirements on EUA approvals. Specifically, HHS may only approve an EUA if, after consulting four specified agencies, at least three of them vote to grant approval. Currently, HHS's authority to approve an EUA, which it has delegated to the Food and Drug Administration, is not limited by the votes of consulting agencies. Additionally, the bill authorizes the use of HHS funds to produce a vaccine before it is licensed or authorized in response to a public health emergency. The bill also establishes the Office of Operation Warp Speed within the HHS Office of the Assistant Secretary for Preparedness and Response to expedite the production of vaccines and medical countermeasures to respond to public health emergencies. With respect to the Strategic National Stockpile, HHS must assess, as part of its annual threat-based review, the levels of and supply chains for materials in the stockpile. HHS must also give priority to domestic manufacturers when procuring materials for the stockpile. If materials cannot be sourced domestically, HHS must give priority to manufacturers that are not located in China.
Tom Cotton (R)
in committee · Arkansas · Senate May 13, 2021

S 1644: Promising Pathway Act

Promising Pathway Act This bill establishes a provisional approval pathway for medicines intended for serious or life-threatening diseases, including illnesses posing a threat of epidemic or pandemic. The period of the provisional approval is for two years and is potentially renewable. The Food and Drug Administration (FDA) must establish a priority review system to evaluate completed provisional approval applications within 90 days of receipt. A provisional approval application may be approved if the FDA determines that (1) there is substantial evidence of safety for the drug; and (2) there is relevant early evidence of efficacy, based on adequate and well-controlled investigations. During the COVID-19 (i.e., coronavirus disease 2019) pandemic, or another epidemic or pandemic, the FDA must accept and review various portions of a provisional approval application on a rolling basis. The manufacturer of a provisionally approved drug must require patients to participate in an observational registry. A manufacturer that fails to comply with registry requirements is subject to civil penalties. A provisionally approved drug must be labeled as such. If a drug that receives provisional approval status is not brought to market within 180 days of the approval, the approval must be rescinded. The bill also limits the liability of a manufacturer of a provisionally approved drug with respect to any claim under state law alleging that the drug is unsafe or ineffective. Private health insurers and federal health care programs shall not deny coverage of a provisionally approved drug on the basis of it being experimental.
Mike Braun (R) · 6 co-sponsors
in committee · Arkansas · Senate May 13, 2021

S 1641: ISRA

Israel Sovereignty Reassurance Act of 2021 or ISRA This bill prohibits using funds made available to the Department of State for FY2022 to implement, administer, or enforce any policy that rescinds the U.S. recognition of the Golan Heights as part of Israel.
Ted Cruz (R) · 17 co-sponsors
Showing 2,965 to 2,976 of 3,364 bills